Linagliptin PCD Pharma Franchise Company

Cafoli Lifecare is a WHO-GMP certified Linagliptin PCD pharma franchise company offering a portfolio of 10 Linagliptin formulations. We supply quality-assured, consistently manufactured Linagliptin products to franchise partners and distributors across India on a monopoly (district-wise) basis.

What is Linagliptin?

Linagliptin is an oral anti-diabetic drug of the DPP-4 inhibitor (gliptin) class. By inhibiting the enzyme dipeptidyl peptidase-4 it raises levels of the incretin hormones GLP-1 and GIP, which enhance glucose-dependent insulin release and suppress glucagon, lowering blood sugar. It is used to improve glycaemic control in type 2 diabetes mellitus. Reference: PubChem.

Available Forms

Our Linagliptin range is available as Tablets, allowing partners to serve diverse prescriptions from a single reliable supplier.

Therapeutic Applications of Linagliptin

Linagliptin is indicated for the management of type 2 diabetes mellitus, either as monotherapy or in combination with metformin, sulfonylureas or insulin. It is commonly prescribed by diabetologists, endocrinologists and general physicians.

Why Linagliptin is a High-Potential Molecule for Distributors

India’s large and expanding type 2 diabetes population makes gliptins a high-growth chronic-therapy segment. Linagliptin has a distinct advantage: it is primarily eliminated via the bile and needs no dose adjustment in renal impairment, making it a preferred choice for elderly and kidney-compromised patients and a compelling, differentiated addition to an anti-diabetic portfolio.

Why Choose Cafoli Lifecare

Cafoli Lifecare offers exclusive monopoly rights, WHO-GMP certified and DCGI-approved formulations, attractive promotional inputs, and the backing of a network of 1000+ franchise partners. Our transparent pricing and dependable supply chain help distributors build a profitable long-term business.

References

1. PubChem - Linagliptin
2. DrugBank - Linagliptin
3. PubMed - Linagliptin research